Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | APAF1 | O14727 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 2/20 | 0.37 |
| ▸ | KIT | P10721 | 2/20 | 0.37 |
| ▸ | KDR | P35968 | 2/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | IGF1R | P08069 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | CIT | O14578 | 1/20 | 0.33 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.33 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.33 |
| ▸ | STK10 | O94804 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12658843 | 0.85 | KDM4E (0.49) | KDM4EMEN1GAAMAPTKMT2A | |
| SCHEMBL31197419 | 0.85 | KDM4E (0.49) | KDM4EMEN1GAAMAPTKMT2A | |
| Tert-Butyl Formate SCHEMBL27672856 | 0.84 | TDP1 (0.40) | KDM4EMEN1GAAMAPTKMT2A | |
| SCHEMBL1265188 | 0.81 | RARB (0.49) | KDM4EMEN1GAAMAPTKMT2A | |
| SCHEMBL2061261 | 0.79 | RARB (0.41) | KDM4EMEN1GAAMAPTKMT2A | |
| SCHEMBL426992 | 0.78 | HTR5A (0.40) | KDM4EMEN1GAAMAPTKMT2A | |
| SCHEMBL9058070 | 0.78 | KDM4E (0.42) | KDM4EMEN1GAAMAPTKMT2A | |
| SCHEMBL2123632 | 0.77 | AR (0.36) | KDM4EMEN1GAAMAPTKMT2A | |
| SCHEMBL4720672 | 0.77 | AR (0.39) | MAPTKMT2ALCKKITKDR | |
| SCHEMBL15811809 | 0.77 | HTR2A (0.49) | MEN1GAAMAPTKMT2AAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250320184-A1 | SARM1 MODULATORS, PREPARATIONS, AND USES THEREOF | SIRONAX LTD (KY) | 2025-10-16 | — | — | US | disclosed |
| WO-2025215582-A1 | SUBSTITUTED PYRAZOLOPYRIDINE AND PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE | GT GAIN THERAPEUTICS SA (CH) | 2025-10-16 | — | — | WO | disclosed |
| EP-4536640-A1 | SARM1 MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2025-04-16 | — | — | EP | disclosed |
| WO-2025054339-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS INHIBITORS OF KIT | ARCUS BIOSCIENCES, INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| WO-2023236920-A1 | SARM1 MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2023-12-14 | — | — | WO | disclosed |
| EP-1979339-A2 | NOVEL CYCLIC UREA DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS | Aventis Pharma S.A. (FR) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007083017-A2 | NOVEL CYCLIC UREA DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2007-07-26 | — | — | WO | disclosed |
| CN-1626534-A | Steroid receptor modulator compounds and methods | LIGAND PHARM INC (US) | 2005-06-15 | — | — | CN | disclosed |
| CN-1172917-C | Steroid receptor modulator compounds and methods | ��λ��ҩ��ɷ�����˾ | 2004-10-27 | — | — | CN | disclosed |
| US-20040186132-A1 | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED | 2004-09-23 | — | — | US | disclosed |
| CN-1175247-A | Steroid receptor modulator compounds and methods | LIGAND PHARM INC (US) | 1998-03-04 | — | — | CN | disclosed |
| US-5696127-A | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-12-09 | — | — | US | disclosed |
| US-5696130-A | Tricyclic steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-12-09 | — | — | US | disclosed |
| US-5696133-A | ADMINISTERING COMPOUND WHICH MODULATES ACTIVITY OF PROGESTERONE RECEPTOR | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-12-09 | — | — | US | disclosed |
| US-5693646-A | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-12-02 | — | — | US | disclosed |
| US-5693647-A | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-12-02 | — | — | US | disclosed |
| US-5688808-A | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-11-18 | — | — | US | disclosed |
| US-5688810-A | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-11-18 | — | — | US | disclosed |
| EP-0800519-A1 | STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS, INC. (US) | 1997-10-15 | — | — | EP | disclosed |
| WO-1996019458-A2 | STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1996-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250320184-A1 | SARM1 MODULATORS, PREPARATIONS, AND USES THEREOF | SARM1, SMN1; SMN2, ADRM1 | KDM4E 3435/4885MEN1 4368/4885GAA 1034/4885 |
| US-20040186132-A1 | Steroid receptor modulator compounds and methods | NR5A1, ESRRA, NR3C2 | KDM4E 3167/4885MEN1 3750/4885GAA 4605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.